vs
ARTIVION, INC.（AORT）与REPUBLIC BANCORP INC（RBCAA）财务数据对比。点击上方公司名可切换其他公司
ARTIVION, INC.的季度营收约是REPUBLIC BANCORP INC的1.2倍（$116.0M vs $94.3M），REPUBLIC BANCORP INC净利率更高（24.2% vs 2.1%，领先22.1%），ARTIVION, INC.同比增速更快（19.2% vs 5.3%），REPUBLIC BANCORP INC自由现金流更多（$161.1M vs $-7.9M），过去两年ARTIVION, INC.的营收复合增速更高（9.1% vs -11.5%）
Artivion, Inc.是一家专注于心血管移植领域的医疗企业，主要供应经深低温冷冻保存的人体组织，同时研发各类医疗器械。旗下核心产品包括经过特殊处理、去除多余细胞物质与抗原的人体心脏瓣膜，以及BioGlue手术粘合剂，可为临床诊疗提供专业支持。
肯塔基州共和银行是美国的一家区域性银行控股企业，提供零售及商业银行全品类服务，涵盖个人存贷款、企业融资、按揭产品及财富管理解决方案，主要服务肯塔基州及周边州的个人消费者和中小企业客户。
AORT vs RBCAA — 直观对比
营收规模更大
AORT
是对方的1.2倍
$94.3M
营收增速更快
AORT
高出13.9%
5.3%
净利率更高
RBCAA
高出22.1%
2.1%
自由现金流更多
RBCAA
多$169.1M
$-7.9M
两年增速更快
AORT
近两年复合增速
-11.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $116.0M | $94.3M |
| 净利润 | $2.4M | $22.8M |
| 毛利率 | 63.1% | — |
| 营业利润率 | 9.2% | 29.3% |
| 净利率 | 2.1% | 24.2% |
| 营收同比 | 19.2% | 5.3% |
| 净利润同比 | 114.7% | 20.0% |
| 每股收益（稀释后） | $0.06 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AORTRBCAA
| Q4 25 | $116.0M | $94.3M | ||
| Q3 25 | $113.4M | $93.5M | ||
| Q2 25 | $113.0M | $93.8M | ||
| Q1 25 | $99.0M | $135.8M | ||
| Q4 24 | $97.3M | $89.5M | ||
| Q3 24 | $95.8M | $88.1M | ||
| Q2 24 | $98.0M | $86.9M | ||
| Q1 24 | $97.4M | $120.3M |
净利润AORTRBCAA
| Q4 25 | $2.4M | $22.8M | ||
| Q3 25 | $6.5M | $29.7M | ||
| Q2 25 | $1.3M | $31.5M | ||
| Q1 25 | $-505.0K | $47.3M | ||
| Q4 24 | $-16.5M | $19.0M | ||
| Q3 24 | $-2.3M | $26.5M | ||
| Q2 24 | $-2.1M | $25.2M | ||
| Q1 24 | $7.5M | $30.6M |
毛利率AORTRBCAA
| Q4 25 | 63.1% | — | ||
| Q3 25 | 65.6% | — | ||
| Q2 25 | 64.7% | — | ||
| Q1 25 | 64.2% | — | ||
| Q4 24 | 63.2% | — | ||
| Q3 24 | 63.7% | — | ||
| Q2 24 | 64.6% | — | ||
| Q1 24 | 64.6% | — |
营业利润率AORTRBCAA
| Q4 25 | 9.2% | 29.3% | ||
| Q3 25 | 11.1% | 40.4% | ||
| Q2 25 | 7.4% | 43.0% | ||
| Q1 25 | 2.2% | 44.1% | ||
| Q4 24 | 2.7% | 25.8% | ||
| Q3 24 | 4.6% | 38.4% | ||
| Q2 24 | 6.6% | 37.0% | ||
| Q1 24 | 26.0% | 32.2% |
净利率AORTRBCAA
| Q4 25 | 2.1% | 24.2% | ||
| Q3 25 | 5.7% | 31.8% | ||
| Q2 25 | 1.2% | 33.5% | ||
| Q1 25 | -0.5% | 34.8% | ||
| Q4 24 | -16.9% | 21.2% | ||
| Q3 24 | -2.4% | 30.1% | ||
| Q2 24 | -2.2% | 29.0% | ||
| Q1 24 | 7.7% | 25.4% |
每股收益（稀释后）AORTRBCAA
| Q4 25 | $0.06 | — | ||
| Q3 25 | $0.13 | — | ||
| Q2 25 | $0.03 | — | ||
| Q1 25 | $-0.01 | — | ||
| Q4 24 | $-0.40 | — | ||
| Q3 24 | $-0.05 | — | ||
| Q2 24 | $-0.05 | — | ||
| Q1 24 | $0.18 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.9M | $220.0M |
| 总债务越低越好 | $215.1M | — |
| 股东权益账面价值 | $448.2M | $1.1B |
| 总资产 | $884.8M | $7.0B |
| 负债/权益比越低杠杆越低 | 0.48× | — |
8季度趋势，按日历期对齐
现金及短期投资AORTRBCAA
| Q4 25 | $64.9M | $220.0M | ||
| Q3 25 | $73.4M | $484.2M | ||
| Q2 25 | $53.5M | $484.8M | ||
| Q1 25 | $37.7M | $793.0M | ||
| Q4 24 | $53.5M | $432.2M | ||
| Q3 24 | $56.2M | $530.9M | ||
| Q2 24 | $55.0M | $400.1M | ||
| Q1 24 | $51.1M | $546.4M |
总债务AORTRBCAA
| Q4 25 | $215.1M | — | ||
| Q3 25 | $214.9M | — | ||
| Q2 25 | $215.6M | — | ||
| Q1 25 | $314.7M | — | ||
| Q4 24 | $314.3M | — | ||
| Q3 24 | $314.0M | — | ||
| Q2 24 | $313.6M | — | ||
| Q1 24 | $313.3M | — |
股东权益AORTRBCAA
| Q4 25 | $448.2M | $1.1B | ||
| Q3 25 | $438.7M | $1.1B | ||
| Q2 25 | $419.9M | $1.1B | ||
| Q1 25 | $294.3M | $1.0B | ||
| Q4 24 | $276.2M | $992.0M | ||
| Q3 24 | $304.7M | $979.7M | ||
| Q2 24 | $295.1M | $955.4M | ||
| Q1 24 | $295.0M | $935.6M |
总资产AORTRBCAA
| Q4 25 | $884.8M | $7.0B | ||
| Q3 25 | $857.7M | $7.0B | ||
| Q2 25 | $838.4M | $7.0B | ||
| Q1 25 | $791.2M | $7.1B | ||
| Q4 24 | $789.1M | $6.8B | ||
| Q3 24 | $803.1M | $6.7B | ||
| Q2 24 | $789.5M | $6.6B | ||
| Q1 24 | $784.0M | $6.9B |
负债/权益比AORTRBCAA
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.49× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 1.14× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 1.06× | — | ||
| Q1 24 | 1.06× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.6M | $168.2M |
| 自由现金流经营现金流 - 资本支出 | $-7.9M | $161.1M |
| 自由现金流率自由现金流/营收 | -6.9% | 170.9% |
| 资本支出强度资本支出/营收 | 23.7% | 7.5% |
| 现金转化率经营现金流/净利润 | 8.06× | 7.37× |
| 过去12个月自由现金流最近4个季度 | $839.0K | $288.6M |
8季度趋势，按日历期对齐
经营现金流AORTRBCAA
| Q4 25 | $19.6M | $168.2M | ||
| Q3 25 | $22.3M | $33.3M | ||
| Q2 25 | $15.0M | $8.4M | ||
| Q1 25 | $-17.0M | $93.2M | ||
| Q4 24 | $10.1M | $149.0M | ||
| Q3 24 | $11.5M | $51.3M | ||
| Q2 24 | $6.1M | $4.0M | ||
| Q1 24 | $-5.5M | $71.2M |
自由现金流AORTRBCAA
| Q4 25 | $-7.9M | $161.1M | ||
| Q3 25 | $17.7M | $30.8M | ||
| Q2 25 | $11.7M | $5.2M | ||
| Q1 25 | $-20.6M | $91.6M | ||
| Q4 24 | $8.7M | $143.2M | ||
| Q3 24 | $7.8M | $49.8M | ||
| Q2 24 | $3.6M | $2.7M | ||
| Q1 24 | $-9.1M | $69.1M |
自由现金流率AORTRBCAA
| Q4 25 | -6.9% | 170.9% | ||
| Q3 25 | 15.6% | 32.9% | ||
| Q2 25 | 10.4% | 5.5% | ||
| Q1 25 | -20.8% | 67.4% | ||
| Q4 24 | 9.0% | 160.0% | ||
| Q3 24 | 8.2% | 56.5% | ||
| Q2 24 | 3.7% | 3.1% | ||
| Q1 24 | -9.3% | 57.5% |
资本支出强度AORTRBCAA
| Q4 25 | 23.7% | 7.5% | ||
| Q3 25 | 4.1% | 2.6% | ||
| Q2 25 | 2.9% | 3.5% | ||
| Q1 25 | 3.7% | 1.2% | ||
| Q4 24 | 1.5% | 6.5% | ||
| Q3 24 | 3.8% | 1.7% | ||
| Q2 24 | 2.6% | 1.5% | ||
| Q1 24 | 3.7% | 1.7% |
现金转化率AORTRBCAA
| Q4 25 | 8.06× | 7.37× | ||
| Q3 25 | 3.42× | 1.12× | ||
| Q2 25 | 11.16× | 0.27× | ||
| Q1 25 | — | 1.97× | ||
| Q4 24 | — | 7.84× | ||
| Q3 24 | — | 1.93× | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | -0.73× | 2.33× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
RBCAA
暂无分部数据
